In this post in the Bill & Melinda Gates Foundation’s “Impatient Optimists” blog, Christine Rousseau, a program officer at the foundation, describes the importance of diagnostics in HIV/AIDS and tuberculosis (TB) care and treatment and writes, “This brings me to the tremendous role that China’s entrepreneurs can play as partners in global health. China is a country with a huge capacity for innovation as well as the resources required to create new products. We believe that China is uniquely positioned to develop new health technologies that can benefit people in the developing world faster and more effectively than product developers elsewhere.” She notes “the HIV and TB teams of the Bill & Melinda Gates Foundation will be presenting the business case for a new generation of diagnostics to Chinese researchers, product developers, and investors at the China Diagnostics Conference in Shanghai on September 25 and 26” (9/24).
Private Sector Involvement
“Severe droughts, rising grain prices and food shortages — the latest headlines are an urgent call for action,” and “it is time to step up our response,” Suma Chakrabarti, president of the European Bank for Reconstruction and Development (EBRD), and Jose Graziano da Silva, director-general of the U.N. Food and Agriculture Organization (FAO), write in a Wall Street Journal opinion piece. On September 13, the EBRD and FAO will convene the Private Sector for Food Security Conference in Istanbul, Turkey, “the largest and most important gathering of companies and decision-makers in agribusiness from the Caspian and Black seas to the Mediterranean … [to] discuss the key role of the private sector in feeding the world,” they note. “The simple truth is that the world needs more food, and that means more production,” they state, adding, “The private sector can be the main engine of such growth.”
“Some academics and non-profit organizations are skeptical of the motives of the increasing number of multinational companies who seek partnerships to address non-communicable diseases (NCDs),” Derek Yach, senior vice president of global health and agriculture policy at PepsiCo and former head of NCDs at WHO, writes in the Huffington Post’s “Impact” blog. He asks, “So how well is the private sector doing in tackling the rising pandemic of NCDs, which cause nearly two out of every three deaths in the world (80 percent of those in developing countries), the four main ones being cancer, cardiovascular disease, chronic respiratory disease and diabetes?” He continues, “The private sector is a major stakeholder in many ways — as employers; makers of food and medicines, sports gear and technology; as corporate citizens and consumers — and wants to be engaged in the global NCD dialogue. We deserve a seat at the table.”
In this AlertNet commentary, GAVI Alliance CEO Seth Berkley discusses how “public-private partnership is part of the GAVI Alliance’s formula for success that has helped countries to immunize 325 million children in our first 10 years, saving more than 5.5 million lives.” Writing last week from the World Economic Forum in Davos, Switzerland, Berkley says, “In fact, public-private partnerships are part of what brings me to Davos this week.”
Thirteen pharmaceutical companies; the governments of the U.S., U.K. and United Arab Emirates; the Bill & Melinda Gates Foundation; the WHO; the World Bank; the Drugs for Neglected Diseases initiative (DNDi); and other global health organizations “announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade,” according to a press release (.pdf) from Global Health Strategies. “In the largest coordinated effort to date to combat NTDs,” the partners will provide 14 billion doses of medications by the end of the decade and share expertise and products to speed research and development of new drugs, the press release notes.
Frontline Health Workers Coalition Launches Initiative To Add 1M Health Care Workers In Developing Countries
The Frontline Health Workers Coalition — which consists of 16 major non-governmental organizations (NGOs) including the Bill & Melinda Gates Foundation, Family Care International, the International Association of Physicians in AIDS Care, and RESULTS — has launched “a new initiative to add one million health care workers in developing countries,” VOA News reports, adding that the “Coalition says training more community-level workers is the most cost effective way to save lives, speed progress on global health threats and promote U.S. economic and strategic interests” (DeCapua, 1/11). “The Coalition, which launched today with the release of a new report (.pdf) focusing on the need for frontline health workers, is calling on the U.S. administration to train and support an additional 250,000 new frontline health workers — and to better support the capacity and impact of existing workers where the need is greatest,” a Coalition press release (.pdf) states (1/11).
In this PLoS Medicine research article, Reed Beall and Randall Kuhn of the Josef Korbel School of International Studies at the University of Denver provide an analysis of trends in compulsory licensing (CL) of pharmaceuticals since the Doha Declaration. “Almost 10 years after the Doha Declaration, we examined the subsequent occurrence of CL episodes, an important direct indicator of treaty impact,” they write. Given that “compulsory licensing activity has diminished greatly since 2006, … the researchers conclude, health advocates who pushed for the Doha Declaration reforms have had little success in engaging trade as a positive, proactive force for addressing health gaps,” according to the article’s Editors’ Summary (1/10).
J&J Will Not Join Medicines Patent Pool; Company’s Pharma Head Says Mechanism Could ‘Cause Disaster’
Pharmaceutical company “Johnson & Johnson has rejected calls to offer patent rights on its HIV medicines to generic drug companies through a” Medicines Patent Pool, created to promote low-cost antiretroviral drugs in low-income countries and the development of new drug combinations and formulations, the Financial Times reports. “Paul Stoffels, worldwide head of pharmaceuticals at J&J, … cautioned that the pool could trigger a ‘mixing and matching’ of medicines that would cause a rapid surge in patient resistance to innovative HIV drugs” that could “cause a huge disaster,” according to the newspaper.
The New York Times examines developments in circumcision technology, after “three studies have shown that circumcising adult heterosexual men is one of the most effective ‘vaccines’ against [HIV] — reducing the chances of infection by 60 percent or more.” The newspaper writes, “[P]ublic health experts are struggling to find ways to make the process faster, cheaper, and safer” and “donors are pinning their hopes on several devices now being tested to speed things up.” The New York Times reports on several circumcision methods currently being tested, including PrePex, which received FDA approval three weeks ago and “is clearly faster, less painful and more bloodless than any of its current rivals” (McNeil, 1/30).
Pharmaceutical company heads and global health leaders gathered at a conference on Monday in London to announce the formation of a large public-private partnership to fight neglected tropical diseases (NTDs) and endorse the “London Declaration on Neglected Tropical Diseases” (.pdf), in which they pledged to work together and track progress. The following is a summary of two opinion pieces and a blog post in response to the news.